In comparisons with unaffected controls, TSPO binding has been shown to be significantly higher in AD and there has been interest in using second-generation TSPO ligands, including [11C]-PBR28, in longitudinal studies and clinical trials of immunomodulatory drugs [3]. This evidence concerns the gene TSPO and Alzheimer disease.